Yuna Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuna Zhao has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Baohong Zhao
Arthritis and Tissue Degeneration Program, David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY 6
1 shared publication- Bin Zhang
Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China 1
1 shared publication Fei Ning
Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China 1
1 shared publicationLi Yu
Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China 1
1 shared publication- Xiaoyu Hu
Westlake University School of Medicine, Hangzhou, Zhejiang, China
1 shared publication Xiaoyu Li
Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China 1
1 shared publication
Latest Publications
- Open Access
- 23 April 2019
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 216 (6) , 1396-1410
Hes1 attenuates type I IFN responses via VEGF-C and WDFY1
Induction of type I interferons (IFNs) is critical for eliciting competent immune responses, especially antiviral immunity. However, uncontrolled IFN production contributes to pathogenesis of autoimmune and inflammatory diseases. We found that transcription factor Hes1 suppressed production of type I IFNs and expression of IFN-stimulated genes. Functionally, Hes1-deficient mice displayed a heightened IFN signature in vivo, mounted enhanced resistance against encephalomyocarditis virus infection, and showed signs of exacerbated experimental lupus nephritis. Mechanistically, Hes1 did not suppress IFNs via direct transcriptional repression of IFN-encoding genes. Instead, Hes1 attenuated activation of TLR upstream signaling by inhibition of an adaptor molecule, WDFY1. Genome-wide assessment of Hes1 occupancy revealed that suppression of WDFY1 was secondary to direct binding and thus enhancement of expression of VEGF-C by Hes1, making Vegfc a rare example of an Hes1 positively regulated gene. In summary, these results identified Hes1 as a homeostatic negative regulator of type I IFNs for the maintenance of immune balance in the context of antiviral immunity and autoimmune diseases.
- 23 April 2019
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 216 (6) , 1396-1410
Open AccessHes1 attenuates type I IFN responses via VEGF-C and WDFY1
Induction of type I interferons (IFNs) is critical for eliciting competent immune responses, especially antiviral immunity. However, uncontrolled IFN production contributes to pathogenesis of autoimmune and inflammatory diseases. We found that transcription factor Hes1 suppressed production of type I IFNs and expression of IFN-stimulated genes. Functionally, Hes1-deficient mice displayed a heightened IFN signature in vivo, mounted enhanced resistance against encephalomyocarditis virus infection, and showed signs of exacerbated experimental lupus nephritis. Mechanistically, Hes1 did not suppress IFNs via direct transcriptional repression of IFN-encoding genes. Instead, Hes1 attenuated activation of TLR upstream signaling by inhibition of an adaptor molecule, WDFY1. Genome-wide assessment of Hes1 occupancy revealed that suppression of WDFY1 was secondary to direct binding and thus enhancement of expression of VEGF-C by Hes1, making Vegfc a rare example of an Hes1 positively regulated gene. In summary, these results identified Hes1 as a homeostatic negative regulator of type I IFNs for the maintenance of immune balance in the context of antiviral immunity and autoimmune diseases.